Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation of $0 in Q2 FY2026
Q2 FY2026 stock-based compensation was $0.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 stock-based compensation of $0 is the 9th largest of the 10 companies compared; the peer median is $11.32M.
- Stock-based compensation amounts to 0.0% of revenue for ATTO, versus a peer median of 80.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.12M | +24.3% | +9.7% | 17.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $9.13M | -54.6% | — | — |
| LTM Mar 2026 | $3.99M | -24.8% | +61.9% | 7.4% | |
| FY2025 | $3.73M | -44.6% | +54.6% | 5821.9% | |
| FY2025 | $0 | — | — | 0.0% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $11.32M | -16.1% | +54.6% | 80.8% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.